

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(81) International Patent Classification 6: C12N 15/62, 15/70, 15/74, 1/21, A61K 39/08 // (C12N 1/21, C12R 1:19, 1:42)		A1	(11) International Publication Number: WO 95/20665
(31) International Application Number: PCT/GB95/00196		(43) International Publication Date: 3 August 1995 (03.08.95)	
(32) International Filing Date: 31 January 1995 (01.01.95)		(33) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GR, HU, JP, KR, KZ, KP, KR, KZ, LJ, LR, LT, LU, LV, MD, MG, MN, MW, MX, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, JP, IT, LJ, MC, NL, PT, SD, OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (BR, MW, SD, SZ).	
(30) Priority Date: 9401795.J 31 January 1994 (01.01.94) GB		(73) Applicant (for all designated States except US): MEDERVA HOLDINGS B.V. (NL/NL); Churchill-Laan 223, NL-1078 ED Amsterdam (NL).	
(72) Inventor; and (75) Inventor/Applicant (for US only): KHAN, Mohammed, An- jum (GB/GB); University of Newcastle, The Dept. of Mi- crobiology Medical School, Framlington Place, Newcastle upon Tyne NE2 4B1 (GB); CHATFIELD, Steven, Neville (GB/GB); Imperial College of Science & Technology, Dept. of Biotechnology, Medeva Vaccine Research Unit, London SW7 2AY (GB); LI, Jingli (CN/CN); Imperial College of Science & Technology, Dept. of Biotechnology, Medeva Vaccine Research Unit, London SW7 2AY (GB).		Published With international search report.	
(74) Agent: HUTCHINS, Michael, Richard et al.; Fry Heath & Spence, The Old College, 53 High Street, Horley, Surrey RH5 7BN (GB).			
(54) Title: EXPRESSION OF HETEROLOGOUS PROTEINS IN ATTENUATED BACTERIA USING THE NTRA-PROMOTERS			
(57) Abstract The invention provides a DNA construct comprising the <i>phtrA</i> promoter sequence operably linked to a DNA sequence encoding one or more heterologous proteins, replicable expression vectors containing the constructs, and attenuated bacteria containing the constructs or vectors. The invention also provides a vaccine composition comprising an attenuated bacterium as defined above, or a fusion protein expressed from a construct as defined above, and a pharmaceutically acceptable carrier.			

BEST AVAILABLE COPY

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MG	Madagascar
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GR	Greece	MX	Mexico
BE	Belgium	GU	Guam	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	ID	Indonesia	NZ	New Zealand
BJ	Benin	IE	Ireland	PL	Poland
BR	Brazil	IL	Israel	PT	Portugal
BT	Bhutan	JP	Japan	RO	Romania
CA	Canada	KZ	Kazakhstan	RU	Russian Federation
CF	Central African Republic	KG	Kyrgyzstan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SI	Slovenia
CI	Cote d'Ivoire	KZ	Kazakhstan	SK	Slovakia
CM	Cameroon	LA	Laos	SN	Senegal
CN	China	LI	Liechtenstein	TD	Chad
CO	Colombia	LU	Luxembourg	TG	Togo
CR	Costa Rica	LV	Latvia	TT	Trinidad and Tobago
CZ	Czech Republic	MC	Monaco	UA	Ukraine
DE	Germany	MD	Republic of Moldova	US	United States of America
DK	Denmark	MG	Madagascar	UZ	Uzbekistan
EE	Estonia	ML	Mali	VN	Viet Nam
FI	Finland	MR	Mauritania		
FR	France	MT	Malta		
GA	Gabon				

VACCINESEXPRESSION OF HETEROLOGOUS PROTEINS IN ATTENUATED BACTERIA USING THE HTRA-PROMOTERS.

This invention relates to DNA constructs, replicable expression vectors containing the constructs, attenuated bacteria containing the constructs and vaccines containing the said bacteria.

In recent years, there has emerged a new generation of live oral salmonella vaccines based upon strains of Salmonella which have been attenuated by the introduction of a non-reverting mutation in a gene in the aromatic biosynthetic pathway of the bacterium. Such strains are disclosed, for example, in EP-A-0322237. The aforesaid live oral salmonella vaccines are showing promise as vaccines for salmonellosis in man and animals, and they can also be used effectively as carriers for the delivery of heterologous antigens to the immune system. Combined salmonella vaccines have been used to deliver antigens from viruses, bacteria, and parasites, eliciting secretory, humoral and cell-mediated immune responses to the recombinant antigens. Combined salmonella vaccines show great potential as single dose oral

SUBSTITUTE SHEET (RULE 26)

multivaccine delivery systems [C. Hormaeche et al, FEMS Symposium No. 63, Plenum, New York; pp 71-83, 1992].

There are problems to be overcome in the development of combined salmonella vaccines. A major consideration is obtaining a high level of expression of the recombinant antigen in the salmonella vaccine so that it will be sufficient to trigger an immune response. However, unregulated high level expression of foreign antigens can be toxic and affect cell viability [I. Charles and G. Dougan, TISTECH 8, pp 117-21, 1990], rendering the vaccine ineffective or causing loss of the recombinant DNA. Several possible solutions to this problem have been described, such as expression from plasmids carrying essential genes, "on-off" promoters or incorporation of the foreign genes into the salmonella chromosome.

An alternative approach to overcoming the aforesaid problem would be to use a promoter which is inducible in vivo, and one such promoter is the E.coli nitrite reductase promoter nirB which is induced under anaerobiosis. Vaccine compositions containing bacteria transformed with constructs comprising the nirB promoter are described in our earlier International Patent Application PCT/GB93/01617.

The present invention relates to the preparation of DNA constructs containing a different inducible promoter, namely the promoter for the htrA gene which encodes a stress induced protein.

SUBSTITUTE SHEET (RULE 26)

The htrA gene is described in K. Johnson et al Mol. Microbiol 1991; 5:401-7 and references cited therein and is an example of a gene encoding a heatshock protein which is produced in response to a temperature increase above 42°C.

Accordingly, in a first aspect, the invention provides a DNA construct comprising the htrA promoter sequence operably linked to a DNA sequence encoding one or more heterologous proteins.

In one embodiment, the invention provides a DNA construct as hereinbefore defined wherein the htrA promoter sequence is operably linked to a DNA sequence encoding a fusion protein of two or more heterologous proteins.

The proteins making up the fusion may be linked by means of a flexible hinge region.

In a further aspect, the invention provides a DNA construct comprising the htrA promoter sequence operably linked to a DNA sequence encoding first and second heterologous proteins wherein the first heterologous protein is an antigenic sequence comprising tetanus toxin fragment C or one or more epitopes thereof.

In a further aspect, the invention provides a replicable expression factor, suitable for use in bacteria, containing a DNA construct as hereinbefore defined.

In another aspect, the invention provides a fusion protein, preferably in substantially pure form, the fusion protein being expressed by a construct as hereinbefore

## SUBSTITUTE SHEET (RULE 26)

defined.

In a further aspect, the invention provides a process for the preparation of an attenuated bacterium which comprises transforming an attenuated bacterium with a DNA construct as hereinbefore defined.

In a still further aspect, the invention provides a host cell, such as a bacterial cell, containing a DNA construct as hereinbefore defined. The DNA construct may be present in extra-chromosomal form, e.g. in a plasmid, or may be integrated into the host (e.g. bacterial) chromosome by methods known per se.

The invention also provides a vaccine composition comprising an attenuated bacterium as hereinbefore defined, or a fusion protein expressed therefrom, and a pharmaceutically acceptable carrier.

The first and second proteins are preferably heterologous proteins and in particular can be polypeptide immunogens; for example they may be antigenic sequences derived from a virus, bacterium, fungus, yeast or parasite. In particular, it is preferred that the first said protein is an antigenic sequence comprising tetanus toxin fragment C or epitopes thereof.

The second protein is preferably an antigenic determinant of a pathogenic organism. For example, the antigenic determinant may be an antigenic sequence derived from a virus, bacterium, fungus, yeast or parasite.

Examples of viral antigenic sequences for the first and/or second heterologous proteins are sequences derived from a type of human immunodeficiency virus (HIV) such as HIV-1 or HIV-2, the CD4 receptor binding site from HIV, for example from HIV-1 or -2, hepatitis A, B or C virus, human rhinovirus such as type 2 or type 14, Herpes simplex virus, poliovirus type 2 or 3, foot-and-mouth disease virus (FMDV), rabies virus, rotavirus, influenza virus, coxsackie virus, human papilloma virus (HPV), for example the type 16 papilloma virus, the E7 protein thereof, and fragments containing the E7 protein or its epitopes; and simian immunodeficiency virus (SIV).

Examples of antigens derived from bacteria are those derived from Bordetella pertussis (e.g. P69 protein and filamentous haemagglutinin (FHA) antigens), Vibrio cholerae, Bacillus anthracis, and E.coli antigens such as E.coli heat labile toxin B subunit (LT-B), E.coli K88 antigens, and enterotoxigenic E.coli antigens. Other examples of antigens include the cell surface antigen CD4, Schistosoma mansoni P28 glutathione S-transferase antigens (P28 antigens) and antigens of flukes, mycoplasma, roundworms, tapeworms, Chlamydia trachomatis, and malaria parasites, eg. parasites of the genus plasmodium or babesia, for example Plasmodium falciparum, and peptides encoding immunogenic epitopes from the aforementioned antigens.

Particular antigens include the full length Schistosoma

SUBSTITUTE SHEET (RULE 26)

mansoni P28, and oligomers (e.g. 2, 4 and 8mers) of the immunogenic P28 as 115-131 peptide (which contains both a B and T cell epitope), and human papilloma virus E7 protein, Herpes simplex antigens, foot and mouth disease virus antigens, simian immunodeficiency virus antigens, and the diphtheria toxin antigens, e.g. the diphtheria toxin ganglioside binding region.

As used herein, references to the htrA promoter refer to the promoter itself or a part or derivative thereof which is capable of promoting expression of a coding sequence. The preferred sequence, and which contains the htrA promoter is: AATTCTATTCCGGAACCTCGCGTTATAAAATGAATCTGACGTACACAGCAATTTA (SEQ.ID.NO.1)

In the constructs of the present invention, the DNA sequence may encode a fusion protein of two or more proteins in which adjacent proteins are separated by a hinge region. The hinge region is a region designed to promote the independent folding of both the first and second proteins by providing both spatial and temporal separation between the domains.

The hinge region typically is a sequence encoding a high proportion of proline and/or glycine amino acids. The hinge region may be composed entirely of proline and/or glycine amino acids. The hinge region may comprise one or more glycine-proline dipeptide units.

The hinge region may, for example, contain up to about


SUBSTITUTE SHEET (RULE 26)

fifteen amino acids, for example at least 4 and preferably 6-14 amino acids, the number of amino acids being such as to impart flexibility between the first and second proteins.

In one embodiment, the hinge region can correspond substantially to the hinge domain of an antibody immunoglobulin. The hinge regions of IgG antibodies in particular are rich in prolines [T.E. Michaelson et al. J. Biol. Chem. 252, 883-9 1977], which are thought to provide a flexible joint between the antigen binding and tail domains.

Without wishing to be bound by any theory, the prolines are thought to form the rigid part of the hinge as the ring structure characteristic of this amino acid hinders rotation around the peptide bond that connects the proline residue with an adjacent amino acid. This property is thought to prevent proline, and adjacent residues, from adopting the ordered structure of an alpha helix or beta strand. Flexibility is thought to be imparted by glycine, the simplest amino acid, with very limited steric demands. Glycine is thought to function as a flexible elbow in the hinge. Other amino acids may be substituted for glycine, particularly those without bulky side-chains, such as alanine, serine, asparagine and threonine.

In one preferred embodiment, the hinge region is a chain of four or more amino acids defining the sequence



wherein Pro is proline, X and Y are each glycine, or an amino

SUBSTITUTE SHEET (RULE 26)

acid having a non-bulky side chain; Z is any amino acid; p is a positive integer; q is a positive integer of from one to ten; and r is zero or a positive integer greater than zero.

The hinge region can be a discrete region heterologous to both the first and second proteins or can be defined by a carboxy-and portion of the first protein or an amino-and portion of the second protein.

In a most preferred aspect, the present invention provides a DNA molecule comprising the htrA promoter operably linked to a DNA sequence encoding first and second polypeptide immunogens linked by a hinge region, wherein the first polypeptide immunogen comprises tetanus toxin fragment C or epitopes thereof.

In another preferred aspect of the invention, there is provided a replicable expression vector, suitable for use in bacteria, containing the htrA promoter sequence operably linked to a DNA sequence encoding first and second polypeptide immunogens linked by a hinge region, wherein the first polypeptide immunogen comprises tetanus toxin fragment C or epitopes thereof.

In a further aspect, the invention provides a DNA construct comprising the htrA promoter operably linked to DNA encoding a first protein and, extending from the 3' end thereof a DNA sequence encoding the hinge region, and downstream thereof, one or more restriction endonuclease sites.

SUBSTITUTE SHEET (RULE 26)

The said protein is preferably an antigenic protein as hereinbefore defined, and in particular is the TetC fragment or epitopes thereof.

Stable expression of the first and second heterologous proteins linked by the hinge region can be obtained *in vivo*. The heterologous proteins can be expressed in an attenuated bacterium which can thus be used as a vaccine.

The attenuated bacterium may be selected from the genera Salmonella, Bordetella, Vibrio, Haemophilus, Neisseria and Yersinia. Alternatively, the attenuated bacterium may be an attenuated strain of enterotoxigenic Escherichia coli. In particular the following species can be mentioned: S.typhi - the cause of human typhoid; S.typhimurium - the cause of salmonellosis in several animal species; S.enteritidis - a cause of food poisoning in humans; S.choleraesuis - a cause of salmonellosis in pigs; Bordetella pertussis - the cause of whooping cough; Haemophilus influenzae a cause of meningitis; Neisseria gonorrhoeae - the cause of gonorrhoea; and Yersinia - a cause of food poisoning.

Attenuation of the bacterium may be attributable to a non-reverting mutation in a gene in the aromatic amino acid biosynthetic pathway of the bacterium. There are at least ten genes involved in the synthesis of chorismate, the branch point compound in the aromatic amino acid biosynthetic pathway. Several of these map at widely differing locations on the bacterial genome, for example, aroA (5-

SUBSTITUTE SHEET (RULE 26)

enolpyruvylshikimate-3-phosphate synthase), aroC (chorismate synthase), aroD (3-dihydroquinone dehydratase) and aroE (shikimate dehydrogenase). A mutation may therefore occur in the aroA, aroC, aroD, or aroE gene.

Preferably, however, an attenuated bacterium harbours a non-reverting mutation in each of two discrete genes in its aromatic amino acid biosynthetic pathway; or harbours a non-reverting mutation in its aromatic biosynthetic pathway and a non-reverting mutation in a regulatory gene such as htrA, OmpR or OsmC. Examples of suitable attenuated bacteria are disclosed in, for example, EP-A-0322237, and EP-A-0400958.

An attenuated bacterium containing a DNA construct according to the invention can be used as a vaccine. Fusion proteins (preferably in substantially pure form) expressed by the bacteria can also be used in the preparation of vaccines. For example, a purified TetC-P28 fusion protein has been found to be immunogenic on its own. In a further aspect therefore, the invention provides a vaccine composition comprising a pharmaceutically acceptable carrier or diluent and, as active ingredient, an attenuated bacterium or fusion protein as hereinbefore defined.

The vaccine may comprise one or more suitable adjuvants.

The vaccine is advantageously presented in a lyophilised form, for example in a capsular form, for oral administration to a patient. Such capsules may be provided with an enteric coating comprising, for example, Eudragit "S", Eudragit "L",

SUBSTITUTE SHEET (RULE 26)

Cellulose acetate, Cellulose acetate phthalate or Hydroxypropylmethyl Cellulose. These capsules may be used as such, or alternatively, the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is advantageously effected in buffer at a suitable pH to ensure the viability of the organisms. In order to protect the attenuated bacteria and the vaccine from gastric acidity, a sodium bicarbonate preparation is advantageously administered before each administration of the vaccine. Alternatively, the vaccine may be prepared for parenteral administration, intranasal administration or intramammary administration.

Preferably, the vaccine composition is adapted for mucosal delivery, eg by oral administration, by intranasal administration or by intrabronchial administration.

The attenuated bacterium containing the DNA construct of the invention may be used in prophylaxis or treatment of a host, particularly a human host but also possibly an animal host. An infection caused by a micro-organism, especially a pathogen, may therefore be prevented by administering an effective dose of an attenuated bacterium according to the invention. The bacterium then expresses a heterologous protein or proteins capable of raising antibody to the micro-organism. The dosage employed will be dependent on various factors including the size and weight of the host, the type of vaccine formulated and the nature of the heterologous protein.

SUBSTITUTE SHEET (RULE 26)

An attenuated bacterium according to the present invention may be prepared by transforming an attenuated bacterium with a DNA construct as hereinbefore defined. Any suitable transformation technique may be employed, such as electroporation. In this way, an attenuated bacterium capable of expressing a protein or proteins heterologous to the bacterium may be obtained. A culture of the attenuated bacterium may be grown under aerobic conditions. A sufficient amount of the bacterium is thus prepared for formulation as a vaccine, with minimal expression of the heterologous protein occurring.

The expression vector is provided with appropriate transcriptional and translational control elements including, besides the htrA promoter, a transcriptional termination site and translational start and stop codons and an appropriate ribosome binding site is provided. The vector typically comprises an origin of replication and, if desired, a selectable marker gene such as an antibiotic resistance gene. The vector may be, for example, a plasmid.

The invention will now be illustrated, but not limited, by reference to the following examples, and the accompanying drawings, in which:

Figure 1 is a schematic illustration of the construction of a plasmid pHTRAL containing the htrA promoter in accordance with one aspect of the invention;

Figure 2 is a schematic illustration of the construction

SUBSTITUTE SHEET (RULE 26)

of a plasmid pHTRA2 containing the htrA promoter and DNA encoding the tetanus toxin C-fragment linked to a hinge region;

Figure 3 illustrates the structure of the plasmid pTECH2;

Figure 4 illustrates the structure of the intermediate plasmid pBD907;

Figure 5 shows the structure of the plasmid pHTRAI prepared in accordance with the scheme shown in Figure 1;

Figure 6 shows the structure of the product plasmid pHTRA2 prepared in accordance with the scheme shown in Figure 2;

Figures 7A to 7B illustrate the influence of temperature shifts on the promoters nirB, groE and htrA; and

Figure 8 shows the expression of lacZ from htrA, nirB and groE in macrophages.

#### EXAMPLE 1

##### Preparation of htrA-TetC-Hinge Construct

As can be seen from Figure 1, the starting material for the preparation of a vector containing the htrA promoter and genes coding for the tetanus toxin C fragment was the plasmid pTETnir15, the structure and preparation of which is disclosed in our earlier application PCT/GB93/01617 (Publication No. WO 94/03615) and references cited therein, e.g. WO-A-92159689.

The pTETnir15 plasmid contains the nirB promoter linked

SUBSTITUTE SHEET (RULE 26)

to the gene encoding the C-fragment of tetanus toxin (TetC). As shown in Figure 1, pTETnir15 was digested with SacII and BamHI and the resulting 2.9kb and 813bp fragments were gel-purified. The 2.9kb fragment was ligated with a 1.74kb fragment derived from the B. pertussis filamentous haemagglutinin (FHA) gene, the fragment having the sequence shown in SEQ.ID.NO.7. The resulting plasmid was designated pBD907 and the restriction map of the plasmid is shown in Figure 5. The purpose of preparing the intermediate plasmid pBD907 was to remove the EcoRI site present in the TetC fragment in order that the nirB promoter sequence could be replaced by the htrA promoter sequence. This was achieved by digesting plasmid pBD907 with EcoRI and BglII. The resulting 4535bp fragment was gel-purified and ligated with the following 55bp oligonucleotides containing the htrA promoter:

Oligo-1 5' AATTCTATTCCGGAACCTCCGTTATAAAATGAATGTGACGTACACAGCAATTTA  
(SEQ.ID.NO.2)

Oligo-2 3' GATAAGGCCCTTGAAGCCCAATATTTTACTTACACTGCATGTCGTTAAATCTAG  
(SEQ.ID.NO.3)

The presence of the promoter in the resulting intermediate plasmid pINT was confirmed by DNA sequencing. The plasmid pINT was then digested with SacII and BamHI and ligated to the 813bp fragment from pTETnir15 to form plasmid pHTRAI. The DNA sequence of pHTRAI is shown in SEQ.ID.NO.4;

SUBSTITUTE SHEET (RULE 26)



15

the htrA region which is defined by the first 55 base pairs, has the sequence

AATTCTATTCCGGAACCTTCGCGTTATAAAATGAATCTGACGTACACAGCAATTTA  
(SEQ.ID.NO.1).

In relation to SEQ.ID.NO.4, GAACTT is -35 box, and TCTGA is -10 box. At 513 and 2235 base pairs respectively are SacII and AlwNI restriction sites.

Plasmid pHTRAI was used to transform Salmonella typhimurium strain BRD509 (deposited under accession number NCTC ....) and the resulting strain, designated BRD935, was checked for expression of TetC fragment by standard methods. Strain BRD935 has been deposited at the National Collection of Type Cultures, Colindale, United Kingdom on... under the accession number.....).

As shown in Figure 2, plasmid pHTRAI was used to prepare a modified construct in which a "hinge" region is present at the C-terminal of the TetC fragment. The nucleotide sequence representing the "hinge" region was obtained from plasmid pTECH2 which has the DNA sequence set forth in SEQ.ID.NO.5, and possesses SacII and AlwNI restriction sites at positions 533 and 2304 respectively. The preparation of this plasmid is disclosed in our earlier Application PCT/GB93/01617 (Publication No. ....)

The pTECH2 plasmid comprises the nirB promoter region

SUBSTITUTE SHEET (RULE 26)

16

linked to the tetanus toxin C fragment which, at its 3' terminal, is linked via a BamHI restriction site to a hinge region encoded a Gly-Pro-Gly-Pro repeat motif along with a number of restriction sites allowing the insertion of genes encoding further polypeptides. A 1.7kb fragment encoding the hinge region and part of the tetanus toxin C fragment region was removed from pTECH2 through digestion with SacII and AlwNI and purified. The DNA sequence of the resulting fragment is shown in SEQ.ID.NO.6.

Plasmid pHTRAI, which encodes the htrA promoter and the tetanus toxin C fragment, but includes no hinge, was digested with SacII and AlwNI and the resulting 2kb fragment was gel-purified.

The 1.7kb fragment (SEQ.ID.NO.6) from pTECH2 and the 2kb fragment from the pHTRAI were ligated to form plasmid pHTRA2 which incorporates a htrA promoter operably linked to the gene for tetanus toxin C fragment, having at the 3' terminal thereof the hinge region.

An attenuated Salmonella typhimurium strain was transformed with vector pHTRA2 and after selection by means of standard techniques, the salmonella strain BRD1062, harbouring the plasmid pHTRA2 was isolated.

Plasmid pHTRA2 serves as an intermediate for the preparation of constructs coding for a fusion protein linked by the hinge region. Thus, in accordance with the techniques described in our earlier Application No. PCT/GB93/01617,

SUBSTITUTE SHEET (RULE 26)

further proteins can be cloned into the restriction endonuclease sites on the hinge region.

#### MATERIALS AND METHODS

##### Bacterial Strains

E. coli HB101 and BRD509 (an attenuated S. typhimurium aroA aroD strain (Deposited under accession number NCTC ....) were used throughout the experiments. The bacteria were grown in Luria broth (LB) or LB solidified with 1.6% w/v agar supplemented with appropriate antibiotics.

##### DNA Manipulations

Plasmid DNA was purified by the alkaline lysis method (R. Maniatis, et al., 1982 Molecular Cloning - A Laboratory Manual, Cold Spring Harbor Laboratory, New York). Restricted DNA fragments were purified from agar gels by the method of Tautz and Rents (1983, "An optimised freeze-squeeze method for the recovery of DNA Fragments from agarose gels". Analytical Biochem., 132, 14-19). Restriction enzymes were supplied by Boehringer Mannheim, Germany and New England Biolabs, USA and were used according to the manufacturer's instructions.

##### DNA Sequencing

SUBSTITUTE SHEET (RULE 26)

DNA for double stranded sequencing was isolated by the method of Stephen et al. (1990, A Rapid Method for Isolating High Quality Plasmid DNA Suitable for DNA Sequencing, Nucleic Acid Research, 18, No. 24, p 7463). Sequencing was carried out using a Sequenase Version 2 kit (USB) and was used according to the manufacturer's instructions.

##### Oligonucleotides

These were synthesised on a SAMI oligonucleotide synthesiser (Biolabs, UK).

#### EXAMPLE 2

##### Preparation of htrA-lacZ Construct

The properties of the htrA promoter were composed with two other inducible promoters, namely the nirB and groE promoters.

##### Sub-cloning of lacZ downstream to nirB, htrA and groE promoters

A DNA fragment encoding a promoterless lacZ gene was purified from plasmid pNAC1871 (Pharmacia) by the low melting point agarose technique, following cleavage of the plasmid with restriction enzymes SalI and BamHI [14]. Plasmids pTETnir-15 [S.N. Chatfield et al., Bio/Technology 10, 888-892]

SUBSTITUTE SHEET (RULE 26)

and ptEThttrA-1 harbouring the nirB and httrA promoters respectively, were digested with SalI and BamHI endonucleases and the purified lacZ encoding fragment was cloned, in-frame, downstream of the promoters. Plasmid pRZ-PES was used to measure expression of  $\beta$ -galactosidase ( $\beta$ -gal) from the groE promoter. pRZ-PES contains the E. coli groE-operon promoter upstream of groES and lacZ genes. It was constructed by sub-cloning a 2.1 Kb EcoRI-HindIII fragment carrying the operon from plasmid pOF39 [O. Fayet et al J. Bacteriol. 171, 1379-1385 (1989)] into pUC19. A novel BglII site was then introduced between the groES and groEL genes using site directed mutagenesis. The EcoRI-BglII fragment carrying the groE promoter and groES gene was cloned into EcoRI-BamHI cut promoter-probe plasmid pRF5255 [P.F. Lambert et al J. Bacteriol. 162, 441-444 (1985)] to give plasmid pRZ-PES. Plasmids, prepared in S. typhimurium LB5010 (r<sup>-</sup>m<sup>-</sup>) [L.R. Bullas et al J. Bacteriol. 256, 471-474 (1983)], were introduced into S. typhimurium strain BRD915 (S. typhimurium SL1344 httrA) [S.N. Chatfield et al Microbial Pathog. 12, 145-151 (1992)] using electroporation. Lac positive recombinants were screened on L agar plates containing ampicillin and X-gal.

#### Effect of changes in environmental conditions on lacZ expression

Bacterial strains harbouring the recombinant plasmids were grown overnight in L-broth, with shaking at 30°C. The

SUBSTITUTE SHEET (RULE 26)

cultures were diluted 1:50 and growth was allowed to continue for an additional 3 hours at 30°C until an OD<sub>600</sub> of 2.8-3.4 was reached. 0.2 ml of each culture was stored at 4°C and used to determine the base-line of  $\beta$ -gal activity. The remaining portions of the cultures were then shifted to different growth conditions as described below and samples were taken at 0, 2, 4, 6 and 24 hours, unless otherwise specified. At each time point the OD<sub>600</sub> was determined and the bacteria were stored at 4°C prior to performing a  $\beta$ -gal assay.

#### Measuring expression in infected HEp-2, Caco-2 and THP 1-macrophage cell lines

Cells were seeded at approximately 10<sup>5</sup> cell per well in twenty four well plates and grown overnight in Dolbecco's modified Eagles medium, without phenol red (ICN Flow), supplemented with 10% (vol/vol) fetal calf serum and 2 mM glutamine at 37°C, in an atmosphere of 5% CO<sub>2</sub>. 10<sup>6</sup> CFU bacteria of the diluted overnight culture were added to the tissue culture cells and incubated at 30°C. At various time points samples of the tissue culture medium were taken to measure  $\beta$ -gal activity in the extra cellular bacteria. The numbers of bacteria in each sample were determined by viable count and the corresponding OD<sub>600</sub> was determined using a standard curve. Infected cells were washed with phosphate buffer saline (PBS) and incubated for an additional hour in the presence of 200 mg/ml of gentamicin to kill extra cellular

SUBSTITUTE SHEET (RULE 26)

bacteria. Thereafter, the cells were lysed using sterile distilled water and vigorous pipetting. 6-gal activity was determined for each cell lysate. The numbers of bacteria in each lysate were determined by viable count and the corresponding OD<sub>490</sub> values were determined using a standard curve.

#### RESULTS

Expression from each of the promoters selected for this study is sensitive to changes in environmental conditions. nirB has been shown previously to respond to changes in anaerobicity. Initial experiments were performed to assess the levels of lacZ expression from each of the promoters, resident on similar multicopy plasmids, harboured within Salmonella vaccine strain BRD915. The influence of temperature shifts on the different promoters is shown in Figure 7. Temperature shifts from 30°C to 37°C (Figure 7A) resulted in an increase in 6-gal enzyme units when lacZ was expressed from the nirB and htrA promoters. No significant increase in 6-gal units was detected from the groE promoter. A temperature shift from 30°C to 42°C resulted in an increase in the number of 6-gal units from all three promoters. The rate of the increase in the level of 6-gal was faster from htrA and nirB compared with groE (Figure 7B). Temperature shifts from 37°C to 42°C resulted in the induction of both nirB and htrA promoters, with more moderate increase in 6-gal

SUBSTITUTE SHEET (RULE 26)

units from groE promoter (Figure 7C).

Expression of 6-gal from the different promoters was also tested by selecting for bacteria that had entered eukaryotic cells. HEp-2, Caco-2 and THP-1 macrophage cell lines were infected with 10<sup>8</sup> bacteria and incubated at 30°C. The number of 6-gal units, determined three hours after infection of HEp-2, showed that expression of lacZ from both htrA and nirB promoters was significantly enhanced (Figure 2). However there was no detectable increase in lacZ expression from groE promoter. Similar results were obtained in infected Caco-2 cells (not shown). In contrast, in the macrophage's intracellular environment, all three promoters were induced (Figure 8). nirB promoter was most affected and groE promoter was least affected (Figure 8). When the number of 6-gal units in the extra-cellular medium of either cell line was determined, no increase in the enzyme activity was seen (not shown).

Since growth within macrophages was found to influence expression from all three promoters, their sensitivity to hydrogen peroxide, commonly found within the phagosome of macrophages, was monitored. Incubating the bacteria at 30°C in 100 µM hydrogen peroxide resulted in no significant effect on the groE and nirB promoters. In contrast, the level of 6-gal was increased from the htrA promoter reaching 10 U above base-line level by 4 hours. This was followed by a rapid decrease to base-line levels by 6 hours (not shown).

SUBSTITUTE SHEET (RULE 26)

Constitutive expression of lacZ from plasmid pLK [M. Szabo et al J. Bacteriol. 174, 7245-7252] was not significantly affected by any of the environmental conditions (not shown).

In this study three environmentally regulated promoters were used to express lacZ gene under different growth conditions. The promoters are representatives of three classes of inducible bacterial promoters: the anaerobically inducible E. coli nirB, the  $\sigma^F$  dependent htrA and  $\sigma^{H2}$ -dependent groE. Expression from the nirB promoter is dependent on the transcription factor FNR which binds between positions -52 and -30 upstream from transcription start. In some cases FNR dependent transcription is modulated together with a second transcription factor NarL. However, plasmid pTETnir-15 used here contains only the FNR dependent bind site.

Bacteria respond to environmental stress conditions by rapid change in the rate of synthesis of many proteins. In many cases the transit induction rapidly adjusts the protein levels to a new steady state. In this study we tested the influence of environmental conditions on the level of 6-gal. We found that temperature shift had a greater effect on htrA promoters compared with groE. This result is in line with the fact that in vivo the htrA promoter is induced before groE (which is  $\sigma^{H2}$ -dependent) and together with  $\sigma^{H2}$ , by  $\sigma^F$  containing RNA polymerase [11, 12]. Surprisingly, the nirB promoter was also enhanced by elevated temperature. Although it is possible that at high temperature the concentration of oxygen

SUBSTITUTE SHEET (RULE 26)

in the growing media is reduced the fact that the temperature shift from 30°C to 37°C brings rapid increase in the 6-gal units expressed from the nirB promoter may suggest that FNR, like other stress protein modulators, responds to a number of environmental stimuli. Similarly, htrA was also induced under anaerobic growth conditions, and therefore it seems that this promoter is either being regulated by factors other than  $\sigma^F$ , or that  $\sigma^F$  is being activated also at low oxygen tension.

For S. typhimurium to retain virulence the bacteria has to be able to survive in macrophages. This survival is dependant on the ability of the bacteria to tolerate a range of toxic killing mechanisms including the production of hydrogen peroxide. Unlike E. coli htrA mutants, S. typhimurium htrA mutants have been found previously not to be killed by elevated temperature, but rather to have impaired ability to survive significant levels of hydrogen peroxide. Interestingly, the htrA promoter was the only one of the test promoters whose expression was increased in the presence of hydrogen peroxide.

In order to determine the influence of the intracellular environment, the level of expression from the three different promoters was monitored after Salmonella harbouring the test plasmids had entered a number of different cultured eukaryotic cell lines. Bacteria were grown in vitro and used to infect eukaryotic cells at 30°C since a temperature shift from 30°C to 37°C dramatically induced both the htrA and the nirB

SUBSTITUTE SHEET (RULE 26)

promoters. We found that while the level of 5-gal expression from both the nirB and htrA promoters increased in all the cell lines tested, groE promoter was induced only in infected macrophages.

SUBSTITUTE SHEET (RULE 26)

SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: MEDEVA HOLDINGS BV
- (B) STREET: CHURCHILL-LAAN 223
- (C) CITY: AMSTERDAM
- (E) COUNTRY: THE NETHERLANDS
- (F) POSTAL CODE (ZIP): 1078 ED

## (ii) TITLE OF INVENTION: VACCINES

## (iii) NUMBER OF SEQUENCES: 7

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)

## (vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: GB 9401795.1
- (B) FILING DATE: 31-JAN-1994

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 55 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

SUBSTITUTE SHEET (RULE 26)

27

- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: NO
- (vi) ORIGINAL SOURCE:
  - (A) ORGANISM: *Salmonella typhimurium*
- (ix) FEATURE:
  - (A) NAME/KEY: promoter
  - (B) LOCATION: 1..55
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:  
 AATTCTATTC CGGAAGCTTCG CGTTATAAAA TGAATCTGAC GTACACAGCA ATTGA 55
- (2) INFORMATION FOR SEQ ID NO: 2:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 55 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single
    - (D) TOPOLOGY: linear
  - (ii) MOLECULE TYPE: DNA (genomic)
  - (iii) HYPOTHETICAL: NO
  - (iii) ANTI-SENSE: NO
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:  
 AATTCTATTC CGGAAGCTTCG CGTTATAAAA TGAATCTGAC GTACACAGCA ATTGA 55
- (2) INFORMATION FOR SEQ ID NO: 3:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 55 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: single

SUBSTITUTE SHEET (RULE 26)

28

- (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (iii) HYPOTHETICAL: NO
- (iii) ANTI-SENSE: YES
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:  
 GATAAGGCCT TGAAGGCCAA TATTTTACTT ACACTGCATG TGTGGTAAA TCTAG 55
- (2) INFORMATION FOR SEQ ID NO: 4:
  - (i) SEQUENCE CHARACTERISTICS:
    - (A) LENGTH: 3712 base pairs
    - (B) TYPE: nucleic acid
    - (C) STRANDEDNESS: double
    - (D) TOPOLOGY: circular
  - (ii) MOLECULE TYPE: DNA (genomic)
  - (iii) HYPOTHETICAL: NO
  - (iii) ANTI-SENSE: NO
  - (ix) FEATURE:
    - (A) NAME/KEY: htrA promoter
    - (B) LOCATION: 1..55
  - (ix) FEATURE:
    - (A) NAME/KEY: SacII restriction site
    - (B) LOCATION: 513
  - (ix) FEATURE:
    - (A) NAME/KEY: AlwI restriction site
    - (B) LOCATION: 2235
  - (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:  
 AATTCTATTC CGGAAGCTTCG CGTTATAAAA TGAATCTGAC GTACACAGCA ATTAGATCT 60

SUBSTITUTE SHEET (RULE 26)

TAATCATCA CAGGAGACTT TCTGATGAA AACCTTGATT GTTGGGTCA CAACGAAGAA 120  
 GACATCGATG TTATCTTGAA AAGTCTTACC ATTCTGAAT TGGACATCAA CAACGATATT 180  
 ATCTCCGACA TCTCTGGTTT CAATCTCTCT GTTATCACAT ATCCAGATGC TCAATTGGTG 240  
 CCGGGCATCA ACGGCAAGC TATCCACCTG GTTAAACAG AATCTTCTGA AGTATCGTG 300  
 CACAAGGCCA TGGACATGCA ATACAACGAC ATGTTCAACA ACTTACCGT TAGCTTCTGG 360  
 CTGGCGGTC CCAAAATTTT TGTTCCTAC CTGGAACAGT ACGGCACTAA CGAGTACTCC 420  
 ATCATCAGCT CTATGAAGAA ACACTCCCTG TCCATCGGCT CTGGTTGGTC TGTTCCTCTG 480  
 AAGGTTAACA ACCTGATCTG GACTCTGAAA GACTCCGGG GCGAAGTTCG TCAGATCACT 540  
 TTCCCGGACC TCCCGGACAA GTTCAACCGG TACCTGGCTA ACAATGGGT TTTCATCACT 600  
 ATCACTAAG ATCTCTCTCT TCTGCTAAC CTGTACATCA ACGGCGTCTT GATGGGCTCC 660  
 GCTGAATCA CTGCTCTGGG CGCTATCGT GAGGACAACA ACATCACTCT TAAGCTGGAC 720  
 CGTTGCAACA ACAACAACA GTACGTATCC ATCGACAAGT TCGGTATCTT CTGCAAGCA 780  
 CTGAACCGA AAGAGATGCA AAACTGTAT ACCAGTACC TGTCTATCAC CTTCCTGGT 840  
 GACTTCTGGG GTAACCGCT GGTATGAC ACCGAATATT ACCTGATCCC GGTAGCTCT 900  
 AGCTTAAG ACGTTCAGT GAAAAATC ACTGACTACA TGTACCTGAC CAACCGCCG 960  
 TCTACACTA ACGGTAACCT GAACATCTAC TACCGAGCTC TGTACAACGG CCGTAAATTC 1020  
 ATCATCAAC GCTACACTCC GAACAACGAA ATCGATTCTT TGGTAAATC TGGTACTTC 1080  
 ATCAAACTGT ACGTTCTTA CAACAACAAC GAACATCTG TTGGTTACCC GAAAGACGGT 1140  
 AACGCTTCA ACAACCTGGA CAGAAATCTG CGTGTGGTT ACAACGCTCC GGGTATCCCG 1200  
 CTGTACAAA AAATGGAAGC TGTAAACTG CGTGAACCTG AAACCTACTC TGTTCAGCTG 1260  
 AAATCTAGC ACGACAAA CGCTTCTCTG GGTCTGGTTG GTACCCACAA CGGTACATC 1320  
 GGTAAACGCC CGAACCTGGA CATCTGATC GCTTCTAAT GGTACTTCAA CCACCTGAAA 1380  
 GACAAATCC TGGGTTGGA CTGGTACTTC GTTCCGACCG ATGAAGGTTG GACCAAGCAC 1440  
 TAAGGATCG CTAGCCCGCC TAATAGCGG GCTTTTTT CTGGGCGAGC GTTGGCTCT 1500  
 GGCACGGGT GCGCATGAC GTGCTCTGT CGTTGAGGAC CCGCTAGCC TGGCGGGGT 1560  
 GCCTTACTGG TTACGAGAT GAATCACCGA TACCGGAGCG AACGTGAAGC GACTGCTCT 1620

SUBSTITUTE SHEET (RULE 26)

GCAAACTGC TGGGACCTGA GCAACAACAT GAATGGTCTT CGGTTCCGT GTTCTGTAAA 1680  
 GTCTGAAC GCGGAAGTCA GCGCTCTCC GCTTCTCCG TCACTGACTC GCTGCGCTCG 1740  
 GTGTTGGG TGGCGGAGC GGTATCAGT CACTCAAAG CGGTAAATAG GTTATCCACA 1800  
 GAATCAGGG ATAAAGCAGG AAGAACATG TGAGCAAAAG GCGCAAAA GCGCAGGAAC 1860  
 CGTAAAGG CCGGTTGCT GCGTTTTT CATAGGCTCC GCGCCCTGA CGAGCATCAC 1920  
 AAAATCGAC GCTCAAGTCA GAGTGGGGA AACCCGACAG GACTATAAG ATACCAGCG 1980  
 TTTCCTCTG GAGCTCCCT CGTGGCTCT CTTGTTCCA CCGTCCGCT TACCGGATAC 2040  
 CTGCTCGCT TCTTCCCTT GGAAGCGTG GCGTTCTC AATGCTCAG CTGATGGTAT 2100  
 CTGAGTCCG TGTAGGCTG TCGTCCAAG CTGGGCTGTG TGCACGAAC CCGGTTTCA 2160  
 CCGACCGCT GCGCTTATC CGTAACTAT CGTCTTGA TCCAACCGGT AAGACAGGAC 2220  
 TTATGCCAC TGGCAGCAG CACTGTAAC AGGATTAGCA GAGCAGGTA TGTAGCGGT 2280  
 GCTACAGAT TCTTGAAGT GTGGCTAAC TACGGCTACA CTAGAAGGAC AGTATTGCT 2340  
 ATCTCGGCT TGTGAAGCC AGTACCTTC GGAJAAAGAG TTGTAGCTC TTGATCCGGC 2400  
 AAACAACCA CCGTGGTAG CCGTGGTTT TTGTTTGA AGCAGCAGT TACGCGAGA 2460  
 AAAAAGAT CTCAAGAAGA TCTTTTATC TTCTTACGG GGTCTGAGC TCACTGGAAC 2520  
 GAAACTCAC GTTAAGGAT TTGGTCTAG AGATTATCA AAAGATCTT CACTTAGATC 2580  
 CTTTAAAT AAAATGAAG TTAAATCA ATCTAAAGTA TATATGATA AACTGGTCT 2640  
 GACAGTACC AATGCTAAT CAGTGAAGCA CCTATCTAG CGATCTGCT ATTCTGTTA 2700  
 TCCATAGTG CCGTACTCC CCGTGTAG ATAACTAGA TACGGAGGG CTACCATCT 2760  
 GCGCCAGTG CTGCAATGAT ACCCGAGAC CCACGCTCAC CCGCTCAGA TTTATCAGCA 2820  
 ATAAACAGC CAGCGGAAG GCGCGAGCC AGAAGTGGT CTGCACTTT ATCGGCTCC 2880  
 ATCCAGTCTA TAAATTTTG CCGGAAGCT AGAGTAAGTA GTTCCGACT TAATAGTTG 2940  
 GCAAGGTTG TTGCAATTG TCGAGGATC GTGGTCTAC GCTCTGCTT TGGTATGGT 3000  
 TCACTCAGT CCGGTTCCA ACGATCAAG CGAGTTACAT GATCCCCAT GTTGTCAAA 3060  
 AAAGCGTTA GCTCCTTGG TCTCCGATC GTTGTCAAA GTAGTTGGC CGCAGTGT 3120  
 TCATCATGG TTATGGCAGC ACTGCATAAT TCTCTACTG TCATGCCATC CGTAAGATGC 3180

SUBSTITUTE SHEET (RULE 26)



31

TTTCTGTGA CTGGTGAGTA CTCACCAAG TCATTCTGAG AATAGTGTAT GCGGCGACCG 3240  
 AGTTGCTCTT GCCCGGGCTC AACACGGGAT AATACCGGCG CACATAGCAG AACTTTAAAA 3300  
 GTGCTCATCA TTGGAAAACG TTCTTGGGGG CGAAAACCTT CAAGGATCTT ACCGCTGTTG 3360  
 AGATCCAGTT CGATGTAACC CACTCTGCGA CCCAACTGAT CTTCAGCATC TTTTACTTTC 3420  
 ACCACCTTTT CTGGGTGAGC AAAAACAGGA AGGCAAAATG CGCAAAAAA GGGAAATAAGG 3480  
 GCGACACGGA AATGTTGAAT ACTCATACTC TTCTTTTTC AATATTATG AAGCAATTAT 3540  
 CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA TTTAGAAAAA TAAACAAATA 3600  
 GGGGTTCCGC GCACATTTC CCGAAAAGTG CCACCTGAGC TCTAGAAAC CATTATTATC 3660  
 ATGACATTAA CCTATAAAA TAGGCGTATC ACGAGGCCCT TTCCTTTCA AG 3712

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 3769 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: circular

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iii) ANTI-SENSE: NO

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TTTCAAGTAA TTGATGTAC ATCAATGGT ACCGCTTGGT GAATCGTTAA GGTAGGCGGT 60  
 AGGGCCGAGA TCTTAATCAT CCACAGGAGA CTCTCTGATG AAAAACCTTG ATTGTTGGGT 120  
 CGACACGAA GAAGCATCG ATGTTATCTT GAAAAGCTT ACCATTCTGA ACTTGGACAT 180  
 CAACAAGAT ATTATCTCCG ACATCTCTGG TTCAACTCC TCTGTTATCA CATATCCAGA 240  
 TGCTCAATTG GTGCGGGGCA TCAACGGCAA AGCTATCCAC CTGGTTAACA ACGAATCTTC 300  
 TGAAGTTATC GTGCACAAGG CCATGGACAT CGAATACAC GACATGTTCA ACACTTCAC 360  
 CGTTAGCTTC TGGCTGCGCG TTCGAAAAGT TTCTGCTTCC CACCTGGAAC AGTACGGCAC 420

SUBSTITUTE SHEET (RULE 26)

32

TAACGAGTAC TCCATCATCA GCTGTATGAA GAACACTGCC CTGTCCATCG GCTCTGGTTG 480  
 GCTGTCTTCC CTGAAGGGA ACAACCTGAT CTGGACTCTG AAAGACTCCG CGGGCGAAGT 540  
 TCGTCAGATC ACTTTCCGCG ACCTGCCGGA CAAGTTCAAC GCGTACCTGG CTAACAAATG 600  
 GGTFTTATC ACTATCACTA ACGATCTCTT GTCTTCTGCT AACCTGTACA TCAACGGCGT 660  
 TCTGATGGCG TCGCTGAAA TCACTGGTCT GGGCGCTATC CCGGAGACA ACAACATCAC 720  
 TCTTAAGCTG GACCGTTGCA ACAACAACAA CCAGTAAGTA TCACTGACA AGTTCGCTAT 780  
 CTCTGCAAA GCACTGAACC CGAAGAGAT CGAAAACCTG TATACAGCT ACCTGTCTAT 840  
 CACCTTCTTG CCGTACTTCT GGGGTAACCC GCTGCTTAC GACACCGAAT ATTACCTGAT 900  
 CCGGTAGCT TCTAGCTCTA AAGAGCTTCA GCTGAAAAC ATCACTGACT ACATGTACTT 960  
 GACCAACCGG CCGTCTACA CTAACGGTAA ACTGAACATC TACTACCGAC GTCTGTACAA 1020  
 CGGCTGAAA TTATCATCA AACGCTACAC TCGGAACAAC GAATCGATT CTTTCTTTAA 1080  
 ATCTGTGAC TTATCAAAAC TGTACGTTTC TTACAACAAC AACGAACACA TGGTTGGTTA 1140  
 CCGGAAGAC GGTAAAGCTT TCAACAACCT GGACAGAATT CTGGGTGTTG GTTACAACGC 1200  
 TCGGGTATC CCGCTGTACA AAAAAATGGA AGCTGTTAAA CTGGGTGACC TGAACACCTA 1260  
 CTCTGTGAG CTGAACCTGT ACGACGACAA AAACGCTTCT CTGGGTCTGG TTGGTACCCA 1320  
 CAACGGTCAG ATCGGTAAAG ACCCGAACCG TGACATCTG ATCGCTTCTA ACTGTAATT 1380  
 CAACCACTG AAAGACAAA TCTTGGGTTG CGACTGGTAC TTGTTCCGA CCGATGAAG 1440  
 TTGACCAAC GACGGGCGCG GGGCTCTAG AGGATCGAT ATCAAGCTTA CTAGTTAATG 1500  
 ATCCGCTAGC CCGCTAATG AGCGGGCTTT TTTTCTCGG GCAGCGTTGG GTCTGGCCA 1560  
 CCGGTGCGCA TGATCTGCT CTGTGCTTG AGGACCGCG TAGGCTGGCG GGGTGGCTT 1620  
 ACTGCTTAC AGAATGAATC ACGATACCG GAGCGAAGT GAAGCGACTG CTGCTGCAAA 1680  
 ACGTCTGGA CCGTGAACAC AACATGAATG GTCTTGGTT TCGGTGTTT GTAAAGTCTG 1740  
 GAAACGCGA AGTCAGCGCT CTTCGGCTTC CTGGCTCACT GACTGGCTGC GCTCGGCTG 1800  
 TCGGCTGCG CGAGCGGAT CAGCTCACTC AAAGCGGTA ATACGGTTAT CCACAGAATC 1860  
 AGGGGATAAC GCAGGAAGA ACATGTGAGC AAAGGCGAG CAAAAGGCCA GGAACCGTAA 1920  
 AAAGGCGCG TTGCTGGCT TTTTCCATAG GCTCGGCCCC CCGACGAGC ATCAGAAAA 1980

SUBSTITUTE SHEET (RULE 26)

33

TCGACGCTCA AGTCAGAGGT GCGGAACCC GACAGACTA TAAAGATACC AGCGGTTTCC 2040  
 CCTTGAAGC TCCCTCGTC GCTCTCTGT TCGACCTG CCGCTTACCG GATACCTGTC 2100  
 CGCCTTTTC CTTCCGGAA GCGTGGCGCT TTCTCAATG TCACGCTGTA GGTATCTCAG 2160  
 TTCGCTGAG GTCGTTGGT CCAAGCTGG CTGTGTGCAC GAACCCCGCG TTCAGCCCGA 2220  
 CCGTGGCGCC TTATCCGGA ACTATCGCT TGAATCCAC CCGTAAGAC ACGACTTATC 2280  
 GCACTGGCA GCAGCCACTG GTAACAGAT TAGCAGAGG AGGTATGTAG GCGGTCTAC 2340  
 AGACTTCTG AAGTGGTGC CTAACACG CTACACTAGA AGACAGTAT TTGTAATCTG 2400  
 CGCTCTGCT AAGCCAGTTA CTTCCGAAA AAGACTTGT AGCTCTTGT CCGGCAACA 2460  
 ACCACCGCT GGTAGCGTG GTTTTTTGT TTGCAAGCAG CAGATTACCG GCAGAAAAA 2520  
 AGGATCTCA GAAGATCCTT TGATCTTTC TACGGGTCT GACGCTCAGT GGAACGAAA 2580  
 CTCAGCTTA GGAATTTTG TCATGAGAT ATCAAAAGG ATCTTCACCT AGATCCTTT 2640  
 AAATTAATAA TGAAGTTTA AATCAATCTA AAGTATATAT GAGTAACTT GGTCTGACAG 2700  
 TTACCAATGC TTAATCAGTG AGGCACCTAT CTCAGCGATC TGTCTATTTC GTTCATCCAT 2760  
 AGTTGCTGA CTCCTCGTC GTAGATAAC TACGATACCG GAGGCGTTAC CATCTGGCCC 2820  
 CAGTCTGCA ATGATACCGG GAGACCCAG CTCACCGCT CCAGATTAT CAGCAATAA 2880  
 CCAGCCAGC GGAAGGCGG AGCGCAGAG TGCTCTGCA ACTTTATCCG CTTCCATCCA 2940  
 GTCTAATAT TGTTCGCGG AAGCTAGAGT AAGTACTCG CCAGTTAATA GTTTGCGCA 3000  
 GGTGTGCC ATTGCTGAG GCATGCTGG GTACGCTCG TCGTTGGTA TGGCTTCA 3060  
 CAGTCCCGT TCCCAAGAT CAAGCGAGT TACATGATC CCATGTTGT GCAAAAAGC 3120  
 GGTAGCTCC TTGCTCTC CGATCTTGT CAGAATAG TTGCGCGCAG TGTATCACT 3180  
 CATGGTATG GCAGCAGTC ATAATCTCT TACTGTATG CCATCCGTAA GATGCTTTC 3240  
 TGTACTGGT GAGTACTCA CCAAGTCAT CTGAGATAG TGTATCGCG GACCGAGTTG 3300  
 CTCCTGCGG GGTCAACAC GGGATAATC CGGCCCAT AGCAGAACTT TAAAGTGCT 3360  
 CATATTGA AAACGTTCT CGGGCGAAA ACTCTAAG ATCTTACCG TGTGAGATC 3420  
 CAGTTCATG TAACTCACT GTGACCCAA CTGATCTCA GCATCTTTA CTTTACCAG 3480  
 CTTTTGCGG TGAGCAAAA CAGGAAGCA AATGCCGA AAAAGGGAA TAAGGGCGAC 3540

SUBSTITUTE SHEET (RULE 26)

34

ACGGAAATGT TGAATACTCA TACTCTTCT TTTCAATAT TATTGAAGCA TTATCAGGG 3600  
 TTATTGCTC ATGAGCGAT ACATATTGA ATGTATTAG AAAATAAAC AAATAGGGT 3660  
 TCCGCGCACA TTCCCGGAA AAGTGCCACC TGACGTCTAA GAACCATTA TTATCATGAC 3720  
 ATTAACCTAT AAAATAGGC GTATCAGAG GCCCTTCTT CTTCAGAA 3760

(2) INFORMATION FOR SEQ ID NO: 6:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1766 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: double

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: DNA (genomic)

(111) HYPOTHETICAL: NO

(111) ANTI-SENSE: NO

(v) FRAGMENT TYPE: internal

(ix) FEATURE:

(A) NAME/KEY: hinge region

(B) LOCATION: 923..934

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

GGCGGAAGTT CGTGAGTCA CTTCCGCGA CCGCCGAGC AAGTCAAGC CGTACCTGGC 60  
 TACCAATGG GTTTTCATCA CTATCACTAA CGATGCTCTG TCTTCTGCTA ACCTGTACAT 120  
 CAACGGCGTT CTGATGGCT CCGTGAAAT CACTGCTCTG GCGCTATCC GTGAGGACAA 180  
 CAACTCACT CTTAAGCTGG ACCGTTGCAA CAACAACAAC CAGTACGAT CCATCGCAA 240  
 GTTCGTATC TTCTGCAAG CACTGAACCC GAAAGAGATC GAAAACTGT ATACAGCTA 300  
 CCGTCTATC ACCTTCTGC GTGACTTCTG GGTAAACCG CTGCTTACG ACACCGAATA 360  
 TTACTGATC CCGGTAGCTT CTAGCTCTAA AGACGTTGAG CTGAAAACA TCACTGACTA 420  
 CATGTACTG ACCAAGCGC CGTCTACAC TAACGGTAAA CTGAACATCT ACTACCGAGC 480

SUBSTITUTE SHEET (RULE 26)

35

TCTGTACAC GGCTGAAAT TCATCATCA ACGCTACACT CCGAACACG AAATCGATT 540  
 TTCTGTTAAA TCTGTGACT TCATCAAACT GTACGTTTCT TACAACAAC ACGAACACAT 600  
 CTTGTGTAC CCGAAGACG GTAAAGCTTT CAACAACCTG GACAGAATTC TCGGTGTTGG 660  
 TTACAACGCT CCGGGTATCC CGCTGTACAA AAAAATGAAA GCTGTAAAC TCGGTGACCT 720  
 GAAACCTAC TCTGTTACG TGAACCTGTA CGACGACAA AACGCTTCTC TGGGTCTGGT 780  
 TGGTACCCAC AACGGTCAGA TCGTAACGA CCGGAACCGT GACATCTGTA TCGCTTCTAA 840  
 CTGGTACTTC AACCACTGA AAGACAAAAT CCGGGTTCG GACTGGTACT TCGTCCGAC 900  
 CGATCAAGGT TGGACCAACG ACGGGCCGGG GCGCTCTAGA GGATCGATA TCAAGCTTAC 960  
 TAGTTAATGA TCGGTAGCC CGCTAATGA CGGGGCTTTT TTTTCTGGG CAGGTTGGG 1020  
 TCTGGCCAC GGGTGGCAT GATCGTCTC CTGTCTTGA GGACCCGGCT AGGCTGGCGG 1080  
 GGTGGCTTA CTGGTAGCA GAATGAATCA CCGATACCG AGCGAAGCTG AAGCGACTGC 1140  
 TCGTCAAAA CGTCTGGAC CTGAGCAACA ACATGAATGG TCTTGGTTT CCGTGTTCG 1200  
 TAAAGTCTG AAACCGGAA GTACGGCTC TTCCGCTTCC TCGCTCACTG ACTCGCTGGC 1260  
 CTCGGTCTT CCGCTGGCC GAGCGTATC AGCTCACTCA AAGCGGTAA TACGTTATC 1320  
 CACAGAATCA GGGGATAACG CAGGAAGAA CATGTAGCA AAGGCCAGC AAAAGGCCAG 1380  
 GAACGTAAA AAGGCCGGT TGTGGCTT TTCCATAGG CTCGCCCCC CTGACGACA 1440  
 TCACAAAAT CGACGCTCA GTACAGGTG GCGAACCCG ACAGGACTAT AAGATACCA 1500  
 GCGGTTTCC CCGGAAGCT CCGTCTGGC CTCTCTGTT CCGACCTGC CGCTTACCG 1560  
 ATACCTGTC GCGTTTCTC CTTCGGGAG CGTGGGCTT TCTCAATGCT CACGCTTAG 1620  
 GTATCTAGT TCGGTGAGG TCGTGGCTC CAAGCTGGG TGTGTCAGC AACCCCGCT 1680  
 TCAGCCGAC CCGTGGCTT TATCGGTAA CTATCTCTT GAGTCAACC CGGTAAGACA 1740  
 CGACTATCG CCACTGGAC CAGCCA 1766

(2) INFORMATION FOR SEQ ID NO: 7:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1736 base pairs

(B) TYPE: nucleic acid

SUBSTITUTE SHEET (RULE 26)

36

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GCGGGCTAC GCGATTGAC GCGGGGCGG GCGGCCATG TACGGCAAGC ACATCAGCT 60  
 GGTGTACAG GATTGAGGC TGGGGGTGG CCGCTCGG AGCTGTCTT CCGCATGGC 120  
 CATCAGCTG TGTGTCAGG CCGAATTCG CTTGGGAC GCGACGGTCC AGCGGGCCC 180  
 GCTCAGCTC AAGGGGCGG GGTCTGTG GCGCGGCAA CTGGCTCCG GGGGGGGGG 240  
 GGTGAACGC CCGGGGCGG GCGCGTGAA GATCGCTCG CCGCAGCGG TTGGAACCT 300  
 CCGGTGCAA GCGGGGCGA AGGTACAGG CAGCTGTTG AATGCCGGG GACGTTGCT 360  
 GGTGTGGGC CCGCAGCGG TCCAGCTTG CCGGGGAGC AGCGGTGAG CGTGTCTCT 420  
 GACCGGGGC GCGGGCTCA AGCGGACAA GCTGTGGCG AGCGGACGG TCGACGTGA 480  
 TGGCAAGCAG GCGGTGCGG TGGGTGCG CAGCAGCAAT GCGGTGTGG TCGGTGCGG 540  
 CCGCGCCCTC AAGCGGGCA AGTGTGCG GACGGGCGA CTGGACGTG ACGGCAAGCA 600  
 GCGGTGAGC CTGGGTTGG TTGGAGCGA CGGTGCGTG TCGGTAGCG CTGGCGGAA 660  
 CTTGGGGGC AAGCAATTG TCTCAATGC CCACTTGTG GTGCTGGGC AGCGGAGGT 720  
 CCGGTGGAT GACGTTGGA GCGACGCG CATGACCGT GTTGGCGAG GAGCGTGGC 780  
 GCGCGCAAC CTGAGTCCA AGGGGCCAT CCGGTACAG GGTGGAGG CCGTCAAGCT 840  
 GCGCAAGCG AACAGCGAG CCGAATTGG CGTGGCGGG CCGGGCAGG TGGATCTGA 900  
 CGACTGAGC GCGCGCGCG GCGCGGATAT CTCGGCGAG GCGCGCTCA ATATCGGCG 960  
 TCGCGCAGC GATAGGATG TGAAGTCTC CCGGACGGC GCTTGTGTA TCGATAGAT 1020  
 GACGGCCCTC GGTGGATCG GCTCAGCG AGCGGCGAG GTGTGCGCA AGGATATGG 1080  
 CAGCGTGGC GCGTCAAG TCGCGCGG CCGCGGCTC AACTGGGG ATGTCEAGTC 1140  
 GATGGGAG GTCCGCGCA CCGCGCGGG CCGCATGAG GTGCGAGAG TCGCGGTGC 1200  
 CCGGACCTT GCGTTCAG CCGCGGAGC GTTGCAGGC GGTTCCTGA AATCGGCGG 1260  
 TCCATGAC GTGAACGGC CGATGCGGT GCGACTGAT GCGCGGAGC CCGCGGGCA 1320

SUBSTITUTE SHEET (RULE 26)

37

ATTGGGGTT TCCAGGACG GGCAGGCTGC GTTGGGCACT CTCGGGCCA AGGGCGAGCT 1380  
 GACGGTATCG GCGCGGGCG GCGGACCGT GCGCGAGTTG AAGTCGCTGG ACAACATCTC 1440  
 CCGGACGGGC GCGGAACCGG TGTGGTTCA GAGCGTCAAC AGCGCGTCCA GGGTCGCCAT 1500  
 TTGGCGCAC GCGCGCGTGG ATGTAGGCAA GCTTTCCGCC AAGAGCGGTA TCGGGCTCGA 1560  
 AGGCTGGGGC GCGGTCGGAG CCGACTCCCT CGGTTCGAC GCGCGATCA GCGTGTCGG 1620  
 GCGGATCGG GTCAGGCTCG ATCAAGCCCG CACTCTGCC GACATTGCC TGGGGGCGGA 1680  
 AGCGCGGCC ACCTGGGGC CGGTGGAGG CCGCGGTTG ATGACGTGC GCGGCG 1736

SUBSTITUTE SHEET (RULE 26)

38

CLAIMS

1. A DNA construct comprising the htrA promoter sequence operably linked to a DNA sequence encoding one or more heterologous proteins.
2. A DNA construct according to Claim 1 wherein the htrA promoter sequence is operably linked to a DNA sequence encoding a fusion protein of two or more proteins.
3. A DNA construct according to Claim 2 wherein the proteins making up the fusion are linked by means of a flexible hinge region.
4. A DNA construct according to Claim 3 wherein the htrA promoter is operably linked to a DNA sequence encoding first and second heterologous proteins wherein the first heterologous protein is an antigenic sequence comprising tetanus toxin fragment C or one or more epitopes thereof.
5. A replicable expression vector, e.g. suitable for use in bacteria, containing a DNA construct as defined in any one of the preceding Claims.
6. A process for the preparation of an attenuated bacterium which comprises transforming an attenuated bacterium with a replicable expression vector as defined in Claim 1.

SUBSTITUTE SHEET (RULE 26)

7. A host cell containing in either chromosomal or extra-chromosomal form, a DNA construct as defined in any one of Claims 1 to 4.
8. A host cell according to Claim 7 which is an attenuated bacterium.
9. A vaccine composition comprising an attenuated bacterium as defined in Claim 8, or a fusion protein expressed from a construct as defined in any one of Claims 1 to 4, and a pharmaceutically acceptable carrier.
10. A method of treatment or prophylaxis of infection in a mammal, e.g. a human, which method comprises administering to the mammal an effective amount of a vaccine composition as defined in Claim 9.

SUBSTITUTE SHEET (RULE 26)




FIGURE 1a

SUBSTITUTE SHEET (RULE 26)

2/9




FIGURE 1b

SUBSTITUTE SHEET (RULE 26)

3/9




FIGURE 2

SUBSTITUTE SHEET (RULE 26)

4 / 9




FIGURE 3

SUBSTITUTE SHEET (RULE 26)

5 / 9




FIGURE 4

SUBSTITUTE SHEET (RULE 26)




FIGURE 5

SUBSTITUTE SHEET (RULE 26)




FIGURE 6

SUBSTITUTE SHEET (RULE 26)



8/9

FIGURE 7A





FIGURE 7B



SUBSTITUTE SHEET (RULE 26)

9/9

FIGURE 7C





FIGURE 8

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/62 C12N15/70 C12N15/74 C12N1/21 A61K39/08 //(C12N1/21, C12R1:19, C12R1:42)		Int. and Application No. PCT/GB 95/00196
According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED IPC 6 C12N A61K		
Documents searched other than maximum documents to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base used, where practical, search terms used)		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	NUCLEIC ACIDS RESEARCH, vol. 16, no. 21, 11 November 1988 IRL PRESS LIMITED, OXFORD, ENGLAND, pages 10053-10067, B. LIPINSKA ET AL. 'Sequence analysis and regulation of the htrA gene of Escherichia coli: a sigma32-independent mechanism of heat-inducible transcription' see page 10057, line 16 - page 10066, line 25 see page 889, left column, line 5 - line 9 --- -/--	1-10
Further documents are listed in the examination of this C. Patent family members are listed in annex.		
Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier document but published on or after the international filing date "C" document which may have doubts as to priority claim(s) or which is cited to establish the publication date of another document or other special reason (as specified) "D" document referring to an oral disclosure, etc. publication or other means "E" document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search 5 April 1995 Name and mailing address of the ISA European Patent Office, P.O. Box 2911 Patankam 2 D-52001 RV Patankam, F.R.G. 5211 Patankam 2 Tel. (+31-70) 340-2000, Telex 31 431 upa nl, Fax (+31-70) 340-2016		
Date of meeting of the international search report 07.04.95 Authorized officer Hornig, H		

Form PCT/ISA/201 (revised June 1992)

page 1 of 3

## INTERNATIONAL SEARCH REPORT

CLASSIFICATION OF SUBJECT MATTER IPC 6 C12N15/62 C12N15/70 C12N15/74 C12N1/21 A61K39/08 //(C12N1/21, C12R1:19, C12R1:42)		Int. and Application No. PCT/GB 95/00196
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GENES & DEVELOPMENT, vol. 3, no. 9, September 1989 CSH LABORATORY PRESS, NEW YORK, US, pages 1462-1473, J.W. ERICKSON AND C.A. GROSS 'Identification of sigmaE subunit of Escherichia coli RNA polymerase: a second alternative sigma factor involved in high-temperature gene expression' see page 1466, right column, line 4 - page 1469, right column, line 27; figure 8 ---	1-10
Y	BIOTECHNOLOGY, vol. 10, no. 8, August 1992 NATURE PUBL. CO., NEW YORK, US, pages 888-892, S.W. CHATFIELD ET AL. 'Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: Development of a single-dose oral tetanus vaccine' cited in the application see page 888, right column, line 45 - line 48 see page 889, left column, line 5 - line 9 see page 891, left column, line 34 - line 39 ---	1-10
Y	NATURE, vol. 351, no. 6326, 6 June 1991 MACMILLAN JOURNALS LTD., LONDON, UK, pages 456-460, C.R. STOVER ET AL. 'New use of BCG for recombinant vaccines' see page 458, right column, line 44 - page 459, left column, line 35 see page 457, right column, line 1 - line 15 ---	1-10
Y	WO, A, 92 15689 (WELLCOME FOUND) 17 September 1992 see page 2, line 1 - line 10 see page 3, line 6 - page 11, line 3 ---	1-10
Y	WO, A, 89 06974 (PRAXIS BIOLOG INC) 10 August 1989 see page 76, line 1 - page 81, line 4; claims 1-107; tables 12-15 see page 26, line 25 - page 27, line 14 see page 25, line 12 - page 26, line 9 ---	1-10
Y	EP, A, 0 432 965 (SMITHKLINE BEECHAM CORP ; US OF AMERICA AS REPRESENTED (US); BIONE) 19 June 1991 see page 16, line 24 - line 29 --- -/--	1-10

Form PCT/ISA/201 (revised June 1992)

page 2 of 3

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/GB 95/00196

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Number of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO, A, 91 15572 (WELLCOME FOUND) 17 October 1991 the whole document	1-10
P, Y	WO, A, 94 03615 (MEDEVA HOLDINGS B V; KHAN MOHAMMED ANJAM (GB); NORMACHE CARLOS ES) 17 February 1994 cited in the application see page 2, line 15 - line 17 see page 4, line 9 - line 15	1-10
P, X	BIOLOGICAL ABSTRACTS, vol. 99, no. 007, Philadelphia, PA, US; abstract no. 095219, see abstract & FEBS MICROBIOL. LETTERS, vol. 125, no. 1, 1995 pages 97-102, P. EVEREST ET AL. 'Expression of LacZ from the htrA, nirB and groE promoters in Salmonella vaccine strain: influence of growth in mammalian'	1-10

Form PCT/ISA/206 (continuation of sheet 1) (July 1992)

page 3 of 3

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/GB95/00196

**Box 8 Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(C)(a) for the following reasons:

- ☒ **Claims Not:**  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 10 (as far as in vivo methods are concerned) is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
- ☐ **Claims Not:**  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, speedily.
- ☐ **Claims Not:**  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 4.4(a).

**Box 11 Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

- ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not advise payment of any additional fee.
- ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims No.:
- ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims No.:

Remark on Present ☐ The additional search fees were accompanied by the applicant's present.  
☐ No present accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

INTERNATIONAL SEARCH REPORT  
information on patent family members

Int. Application No.  
PCT/GB 95/00196

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9215689	17-09-92	AU-A- 1350892	06-10-92
		CZ-A- 9301005	19-01-94
		EP-A- 0574466	22-12-93
		WO-A- 9215688	17-09-92
		HU-A- 66833	10-01-95
		JP-T- 6505158	16-06-94
WO-A-8906974	10-08-89	AT-T- 109008	15-08-94
		AU-B- 634153	18-02-93
		AU-A- 3065409	25-08-89
		DE-D- 68917126	01-09-94
		DE-T- 68917126	02-02-95
		EP-A- 0399001	28-11-90
EP-A-0432965	19-06-91	JP-T- 3502691	20-06-91
		AU-B- 634837	04-03-93
		AU-A- 6777490	13-06-91
		CA-A- 2031468	09-06-91
		CN-A- 1053814	14-08-91
		JP-A- 6073097	15-03-94
WO-A-9115572	17-10-91	AU-A- 7541791	30-10-91
		CA-A- 2079463	01-10-91
		EP-A- 0524205	27-01-93
		HU-A- 65496	28-06-94
		NZ-A- 237616	25-03-94
WO-A-9403615	17-02-94	AU-B- 4719393	03-03-94
		FI-A- 950396	30-01-95

Form PCT/GA/28 (patent family search) (July 1992)